Where Medicine Meets Ecology

The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against infectious pathogens. Alterations of the human microbiome are increasingly recognized as a key factor in development of immune and infectious diseases.

We rationally design medicines based on consortia of human commensal bacteria to treat disease, using insights from microbial ecology, mucosal immunology, and human interventional studies.

We have spent years perfecting the process necessary to deliver consistent, standardized pharmaceutical-grade drug product based on defined bacterial consortia.

A History of Breakthrough Science in Microbial Ecology and Immunology


Dutch scientist Antonie van Leeuwenhoek is the first person to observe bacteria, by scraping plaque from his own teeth and inspecting it through one of his handcrafted microscopes. His pioneering work contributed to establishing microbiology as a scientific discipline.

Image Credit

Photo Credit: Photo by Don Hamerman


Carl Woese rewrites the Tree of Life with the discovery of Archaea. He pioneers the use of marker genes such as the 16S ribosomal gene as a method to distinguish between microbial lineages, greatly expanding our knowledge of the microbial world.


Vedanta cofounder Alexander Rudensky publishes key work describing the role of the FOXP3 gene in the process by which T cells become regulatory T cells, which can prevent autoimmunity.


David Relman's group publishes seminal work highlighting the great diversity of human-associated bacteria and urges consideration of a “second human genome project” aimed at cataloguing the thousands of microbes that live in association with humans.


The NIH launches the Human Microbiome Project to enable the comprehensive characterization of bacteria that live in association with humans.


Vedanta cofounders Dan Littman and Kenya Honda show that murine-associated bacteria (2009) and human-associated bacteria (2010) can induce intestinal Th17 cells, opening new avenues for the treatment of autoimmune disease via manipulation of the microbiome.


Vedanta Biosciences launched by PureTech Health and founders Ruslan Medzhitov, Alexander Rudensky, Dan Littman, Kenya Honda, and Brett Finlay, scientific pioneers in immunology and the human microbiome.


Vedanta opens Cambridge state-of-the art facility for discovery and GMP manufacturing of bacterial consortia drugs.


Vedanta granted foundational patents in the microbiome field in the US and EU broadly covering drugs based on bacterial consortia containing Clostridium bacteria.


Vedanta initiates first-ever studies with defined consortia (for cancer, CDI, food allergy) and demonstrates safety and long-term colonization in VE303/VE202 studies.


The Opposition Division of the European Patent Office has upheld Vedanta’s foundational patent EP2575835 strengthening Vedanta’s intellectual property position. The upheld patent claims broadly cover compositions of Clostridial bacterial species for use in infectious and allergic disease. 


CONSORTIUM Study meets primary endpoint, demonstrating the safety and efficacy of VE303 in reducing C.difficile infection recurrence and triggering BARDA funding to support a Phase 3 trial. This milestone represents the most advanced study of a rationally-designed defined bacterial consortium.


Vedanta unveils state-of-the-art, multi-product CGMP manufacturing facility to supply the planned Phase 3 clinical trial and potential commercial launch of VE303 in Clostridioides difficile infection

Slide to Learn More

What Makes Us Unique

Founded by Scientific Leaders in the Fields of Immunology and Microbiome

Our scientific founders have pioneered our modern understanding of how the immune system senses microbes, and contributed seminal discoveries to the microbiome field, including the identification of immune-regulating and immune-potentiating bacteria that live in association with humans.


Scientific Co-founders

Board of Directors



PureTech is a a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others.


Gates Foundation Strategic Investment Fund leverages a suite of investment tools partner with entrepreneurs, companies and other organizations to create incentives that harness the power of private enterprise to create change for those who need it most in areas of global development, global health and education.

Rock Springs Capital

Rock Springs Capital is an investment company with advisory activities that include management services to security portfolios and portfolio management for businesses or institutional clients.

Hambro Perks

Hambro Perks is is an international investment firm focused on private technology investing.

Health for Life Capital (Seventure)

Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure has invested in innovative businesses with high growth potential in digital technologies in France and Germany and in the life sciences field across Europe and North America, with currently over €500m in assets under management as of the end of 2014.


Bristol Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases including oncology, cardiovascular, immunoscience and fibrosis.

JSR Corporation

The Life Sciences Business at JSR Corporation, with the expanded range of global strategic partners from both inside and outside the JSR group, is focused on materials targeting in-vitro diagnostics, research reagents and biopharmaceutical manufacturing.

Shumway Capital

Shumway Capital is a growth equity investment firm that partners with management teams to help accelerate their companies’ growth and realize their vision.

FC Capital

FC Capital is a China-based biomedical-focused private equity firm specializing in global healthcare investments, with an emphasis in investing in early stage development and expansion stage biotechnology companies targeting investment in Greater China, U.S. and European countries.

Partners Investment

From ventures to enterprises in the mid-late stages, Partners Investment is an independent investment firm specialized in bringing high potential ventures to the spotlight.

QUAD Investment Management

QUAD Investment Management is a fundamental equities investment firm. QUAD aims to generate alpha through a deep understanding of cyclical and secular industry trends and corporate strategy, management quality and drivers of company performance.

SV Investment

SV Investment is a strategic investment partner and intends to provide a solution to successful companies with rich corporate financial consulting experience and network.


Shinhan Alternative Investment Management Inc., fully financed by Shinhan Financial Group, was established in 2004 as the first private equity fund management firm in Korea. It utilizes long-term strategies as well as advanced capabilities to provide clients with a wide variety of differentiated investment opportunities.